Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.
Parola S, Oing C, Rescigno P, Feliciano S, Carlino F, Pompella L, Marretta AL, De Santo I, Viggiani M, Muratore M, Facchini BA, Orefice J, Cioli E, Sparano F, Mallardo D, De Giorgi U, Palmieri G, Ascierto PA, Ottaviano M. Parola S, et al. Among authors: de santo i. Front Genet. 2024 Nov 29;15:1480417. doi: 10.3389/fgene.2024.1480417. eCollection 2024. Front Genet. 2024. PMID: 39678373 Free PMC article. Review.
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
Schettini F, Nucera S, Brasó-Maristany F, De Santo I, Pascual T, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rivera P, Rodríguez AB, Martínez-Sáez O, Ganau S, Sanfeliu E, González-Farre B, Vidal Losada MJ, Adamo B, Cebrecos I, Mension E, Oses G, Jares P, Vidal-Sicart S, Mollà M, Muñoz M, Prat A. Schettini F, et al. Among authors: de santo i. ESMO Open. 2024 Jul;9(7):103619. doi: 10.1016/j.esmoop.2024.103619. Epub 2024 Jun 28. ESMO Open. 2024. PMID: 38943737 Free PMC article.
Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series.
Fontanelli L, Pizzanelli C, Milano C, Cassano Cassano R, Galimberti S, Rossini MI, Santo I, Turco F, Bonanni E, Siciliano G, Orciuolo E, Baldacci F. Fontanelli L, et al. Among authors: santo i. Neurol Sci. 2023 Sep;44(9):3291-3297. doi: 10.1007/s10072-023-06841-6. Epub 2023 May 10. Neurol Sci. 2023. PMID: 37160803 Free PMC article.
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
Schettini F, Martínez-Sáez O, Falato C, De Santo I, Conte B, Garcia-Fructuoso I, Gomez-Bravo R, Seguí E, Chic N, Brasó-Maristany F, Paré L, Vidal M, Adamo B, Muñoz M, Pascual T, Ciruelos E, Perou CM, Carey LA, Prat A. Schettini F, et al. Among authors: de santo i. ESMO Open. 2023 Jun;8(3):101214. doi: 10.1016/j.esmoop.2023.101214. Epub 2023 Apr 17. ESMO Open. 2023. PMID: 37075698 Free PMC article.
Cardiac Amyloidosis: A Rare Cause of Recurrent Chylothorax.
Patel R, Shah Z, Santo I, Anwer F. Patel R, et al. Among authors: santo i. Cureus. 2022 May 9;14(5):e24861. doi: 10.7759/cureus.24861. eCollection 2022 May. Cureus. 2022. PMID: 35702470 Free PMC article.
SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination.
Trabace L, Pace L, Morgese MG, Santo IB, Galante D, Schiavone S, Cipolletta D, Rosa AM, Reveglia P, Parisi A, Tucci P, Pepe G, Sacco R, Foschino Barbaro MP, Corso G, Fasanella A. Trabace L, et al. Among authors: santo ib. Viruses. 2022 Apr 15;14(4):814. doi: 10.3390/v14040814. Viruses. 2022. PMID: 35458544 Free PMC article.
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Caputo R, Cianniello D, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. De Angelis C, et al. Among authors: de santo i. ESMO Open. 2021 Apr;6(2):100097. doi: 10.1016/j.esmoop.2021.100097. ESMO Open. 2021. PMID: 33926709 Free PMC article. No abstract available.
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. De Angelis C, et al. Among authors: de santo i. ESMO Open. 2021 Apr;6(2):100054. doi: 10.1016/j.esmoop.2021.100054. Epub 2021 Feb 16. ESMO Open. 2021. PMID: 33601296 Free PMC article. Clinical Trial.
59 results